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ABSTRAK 
KAJIAN KE ATAS KESAN DEXMEDETOMIDINE DAN  FENTANYL  
      DITAMBAH KEPADA BUPIVACAINE  UNTUK BIUS SEPARUH BADAN 
    UNTUK  PEMBEDAHAN ORTOPEDIK DI BAHAGIAN KAKI 
 
Pengenalan: Kami menyelidik kesan penambahan dexmedetomidine jika dibandingkan 
dengan fentanyl dalam bius separuh badan dalam mempercepatkan permulaan bius, 
memanjangkan kesan bius dan mengurangkan penggunaan ubat tahan sakit yang lain 
selepas pembedahan. 
Objektif: Ini adalah kajian prospektif secara rawak di mana kami meletakkan pesakit 
dalam salah satu kumpulan yang menerima dexmedetomidine atau fentanyl.  Pesakit 
tidak mengetahui samada mereka menerima dexmedetomidine atau fentanyl. Kami 
menyelidik samada penambahan dexmedetomidine dengan bupivacaine untuk bius 
separuh badan dapat mempercepatkan permulaan bius, memanjangkan kesan bius, 
mempunyai kesan buruk yang rendah dan mengurangkan penggunaan ubat tahan sakit 
selepas pembedahan. Kajian ini dijalankan di Hospital Universiti Sains Malaysia, 
Kelantan. 
Kaedah kajian: : Seramai 64 pesakit dibahagikan secara rawak untuk menerima 
dexmedetomidine atau fentanyl ditambah dengan bupivacaine untuk bius separuh 
badan. Kami mengumpul maklumat mengenai masa permulaaan kesan ubat bius keatas 
kekebasan sehingga T10 dan tiada pergerakan kaki, masa mulanya kekebasan kulit 
hilang dan adanya pergerakan kaki, kesan buruk seperti loya, muntah, gatal gatal badan, 
tekanan darah dan degupan jantung rendah serta masa pesakit meminta ubat tahan sakit 
selepas pembedahan.  Kami juga mencatatkan jumlah ubat voltaren yang diminta dalam 
xiii 
 
24 jam pertama. Penilaian data ini dibuat oleh kakitangan bius yang tidak mengetahui 
jika pesakit menerima dexmedetomidine atau fentanyl. 
Keputusan: Kami mendapati pesakit yang menerima dexmedetomidine mempunyai 
min masa lebih lama untuk permintaan ubat tahan sakit voltaren iaitu 8.84±0.57 (jam) 
berbanding fentanyl 7.53±0.57 (jam) (p<0.001). Min penggunaan ubat voltaren dalam 
24 jam didapati signifikan lebih rendah 51.56±8.84 mg untuk kumpulan 
dexmedetomidine (p<0.001) berbanding fentanyl 92.19±36.17 mg. Bius separuh badan 
didapati bermula lebih cepat iaitu 2.88±0.71 minit dan lebih lama tempoh bius iaitu 
323.75±20.28 minit untuk kumpulan dexmedetomidine secara signifikan( p<0.001) 
berbanding fentanyl iaitu hanya 5.09±1.35 minit untuk bermulanya bius dan bertahan 
selama hanya 256.56±33.76 minit. Didapati tiada perbezaan diantara kedua-dua ubat 
kajian tersebut dalan kesan sampingannya. 
Kesimpulan: Kajian ini mendapati bahawa dengan penggunaan dexmedetomidine 
untuk tambahan kepada bupivacaine untuk bius separuh badan dapat mempercepatkan 
permulaan bius, tahan lebih lama dan mengurangkan penggunaan ubat tahan sakit 
selepas pembedahan terdapat pengurangan ketara dalam skor kesakitan sehingga 2 jam 
selepas pembedahan ortopedik bahagian kaki.  
Kata kunci: dexmedetomidine, ubat bius separuh badan, fentanyl, bupivacaine, 
pembedahan ortopedik bahagian kaki 
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ABSTRACT 
EFFECT IN COMPARISON BETWEEN INTRATHECAL 
DEXMEDETOMIDINE AND INTRATHECAL FENTANYL ADDED TO 
BUPIVACAINE IN LOWER LIMB ORTHOPAEDIC SURGERIES 
 
Introduction: Various adjuvants have been used with local anaesthetics in spinal 
anaesthesia to avoid intraoperative visceral and somatic pain and to provide prolonged 
postoperative analgesia. Dexmedetomidine, the new highly selective α2-agonist drug, is 
now being used as a neuraxial adjuvant.  
Objectives: The purpose of this study was to evaluate the onset and duration of sensory 
and motor block as well as postoperative analgesia and adverse effects of 
dexmedetomidine or fentanyl given intrathecally with hyperbaric 0.5% bupivacaine for 
spinal anaesthesia in lower limb orthopaedic surgeries. This study was conducted in 
Hospital Universiti Sains Malaysia, Kelantan. 
Methodology: Sixty four patients classified as American Society of Anesthesiologists 
(ASA) status I and II scheduled for lower limb orthopaedic surgeries were prospectively 
studied. Patients were randomly allocated to receive intrathecally either 2.5 mls 
hyperbaric 0.5% bupivacaine plus 5 µg dexmetedomidine (n=32) or 2.5 mls hyperbaric 
0.5% bupivacaine plus 25 mg fentanyl (n = 32), the onset time to reach peak sensory 
and motor level, the regression time for sensory and motor block, haemodynamic 
changes, postoperative time to rescue analgesia with total dosage of voltaren in first 24 
hours and side effects were recorded by an anaesthetist colleague blinded to the groups. 
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Results: Patients in the dexmedetomidine group had a significantly longer sensory and 
motor block time than patients in fentanyl group. The mean time of sensory regression 
to S1 was 323.75±20.28 min in dexmedetomidine group and 256.56±33.76 min in 
fentanyl group (P<0.001). The mean regression time of motor block to reach modified 
Bromage 0 was 271.56±24.64 min in dexmedetomidine group and 202.81±44.09 min in 
fentanyl group (P<0.001). Postoperative analgesic requirements were less and time to 
rescue analgesia were prolonged in dexmedetomidine group compared to fentanyl. 
Mean time to rescue analgesia was 8.84±0.57 minute in dexmedetomidine group 
compared to 7.53±0.57 minutes in fentanyl group (p<0.001). There were no significant 
difference in the adverse effect of both the drugs. 
Conclusions: Intrathecal dexmedetomidine is associated with prolonged motor and 
sensory block, haemodynamic stability, and reduced demand for rescue analgesics in 24 
h as compared to fentanyl. 
Keywords: Bupivacaine, dexmedetomidine, fentanyl, spinal anaesthesia 
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CHAPTER 1 
INTRODUCTION 
1.1 Adjuvant drugs 
Adjuvant drugs are pharmacological agents possessing little pharmacological 
effect by themselves and enhance or potentiate the action of other drugs when given at 
the same time. Neuraxial drug administration describes the technique of delivering 
analgesics and adjuvant drugs in close proximity to the spinal cord either intrathecally 
into cerebrospinal fluid (CSF) or epidurally into the epidural space. 
 
Drugs deposited into CSF or epidural space traverses different meningeal layers 
to gain access to receptors located in the spinal cord gray matter. Drugs absorbed by the 
systemic circulation also reach the central nervous system (CNS) to produce its effects 
(Bakshi, Chatterjee et al. 1984). 
 
Neuraxial analgesia is achieved in the perioperative period with local anaesthetic 
(LA) drugs. Adjuvant drugs modify LA effects and reduce side effects. Perioperatively 
these drugs affect: 
1. Latency i.e. time of onset of LA block 
2. Duration of analgesia i.e. duration of sensory and motor block 
3. Quality of analgesia i.e. complete, incomplete (partial or patchy analgesia 
requiring supplemental drugs) 
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Postoperatively adjuvant drugs affect: 
1. Analgesic gap i.e. time interval between subsequent doses administered 
2. Quality of analgesia i.e. patient satisfaction of pain relief 
3. Side effects i.e. reduction of untoward effects of LA drugs 
 
Neuraxial anaesthesia and analgesia provide solid analgesic effect by inhibiting 
nociceptive transmission from peripheral to central neuronal system (Wu, Wang et al, 
2014). However, their analgesic advantages might be limited by the short life of current 
local anaesthetics (LAs), and, especially, be weakened during postoperative pain 
control. The analgesic duration can be prolonged by increasing the dose of LA, with  
accompanied increased risk of systemic and potential neurotoxicity. 
 
Therefore, adjunct analgesic strategy is an alternative to prolong duration of 
analgesia and decrease the potential risk of side effects by reducing the dose of 
individual LA. Several neuraxial adjuvants, including clonidine, dexmedetomidine, 
opioids, dexamethasone, ketamine, magnesium and midazolam have demonstrated the 
synergistic analgesic effect with LAs with varying degrees of success. 
 
Knowledge and use of adjuvant drug therapy has rendered neuraxial analgesia 
more effective in the management of both acute and chronic pain conditions. 
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1.2 Subarachnoid block 
The use of subarachnoid block has become an established and reliable method of 
providing anaesthesia for lower abdominal and lower limb surgery. Even though present 
with the risk of paralysis, subarachnoid block still remains a very effective and safe 
anaesthetic technique for lower abdominal and lower limb surgery. This technique is 
affordable and effort should be made to increase patient awareness and its acceptability 
in the new millennium. 
 
Spinal anaesthesia has progressed greatly since 1885 and is used successfully in 
a number of different clinical situations. However, anatomy, choice of local anaesthetic, 
physiologic effects of spinal anaesthesia, patient positioning, and the approach to spinal 
anaesthesia procedure must all be considered. The patient should be aware regarding the 
possible side effects and complications that can occur from performing a spinal 
anaesthetic in order to obtain informed consent before the procedure. If all of these 
factors are conducive for the patient to receive a spinal anaesthetic, care must be taken 
to prevent complications. Learning how to perform spinal anaesthesia is an invaluable 
skill that all anaesthesiologists should have in their armamentarium. 
 
There are absolute and relative contraindications to spinal anaesthesia. The 
absolute contraindications includes patient refusal, infection at site of injection, 
hypovolaemia, indeterminate neurologic disease, coagulopathy and increased 
intracranial pressure. Relative contraindications include sepsis distinct from the 
anatomic site of puncture (e.g., chorioamnionitis or lower extremity infection) and 
unexpected prolonged duration of surgery. In the latter case, if the patient is on 
antibiotics and the vital signs are stable, spinal anaesthesia may be considered. 
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In reviewing the functional anatomy of spinal anaesthesia, an intimate 
knowledge of the spinal column, spinal cord, and spinal nerves must be present. This 
chapter reviews briefly the curves of the vertebral column, the ligaments of the spinal 
column, membranes and length of the spinal cord, and passage of the spinal nerves from 
the spinal cord.  
 
The vertebral column consists of 33 vertebrae: 7 cervical, 12 thoracic, 5 lumbar, 
5 sacral, and 4 coccygeal segments. The vertebral column usually contains three curves. 
The cervical and lumbar curves are convex anteriorly, and the thoracic curve is convex 
posteriorly. The vertebral column curves, along with gravity, baricity of local 
anaesthetic, and patient position, influence the spread of local anaesthetics in the 
subarachnoid space.  
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       Figure 1.1: The spinal column is seen from a lateral view. All of the vertebrae,  
                     intervertebral discs, and intervertebral foraminae are shown. 
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Five ligaments hold the spinal column together. The supraspinous ligaments 
connect the apices of the spinous processes from the seventh cervical vertebra (C7) to 
the sacrum. The supraspinous ligament is known as the ligamentum nuchae in the area 
above C7. The interspinous ligaments connect the spinous processes together. The 
ligamentumflavum, or yellow ligament, connects the laminae above and below together. 
Finally, the posterior and anterior longitudinal ligaments bind the vertebral bodies 
together.  
 
 
 
Figure 1.2: A cross section of the spinal canal is shown with the ligaments, vertebral  
      body, and spinous processes. 
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The three membranes that protect the spinal cord are the dura mater, arachnoid 
mater, and pia mater. The dura mater, or tough mother, is the outermost layer. The dural 
sac extends to the second sacral vertebra (S2). The arachnoid mater is the middle layer, 
and the subdural space lies between the dural mater and arachnoid mater. The arachnoid 
mater, or cobweb mother, also ends at S2, like the dural sac. The pia mater, or soft 
mother, clings to the surface of the spinal cord and ends in the filumterminale, which 
helps to hold the spinal cord to the sacrum. The space between the arachnoid and pia 
mater is known as the subarachnoid space, and spinal nerves run in this space, as does 
CSF. 
             
Figure 1.3: The spinal cord is shown along with the dorsal root ganglia and ventral         
rootlets, spinal nerves, sympathetic trunk, rami communicantes, and pia, arachnoid, and 
dura mater. 
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When performing a spinal anaesthetic using the midline approach, the layers of 
anatomy that are traversed (from posterior to anterior) are skin, subcutaneous fat, 
supraspinous ligament, interspinous ligament, ligamentum flavum, dura mater, subdural 
space, arachnoid mater, and finally the subarachnoid space.  
 
When the paramedian technique is applied, the spinal needle should traverse the 
skin, subcutaneous fat, ligamentum flavum, dura mater, subdural space, arachnoid 
mater, and then pass into the subarachnoid space.The spinal nerve roots and spinal cord 
serve as the target sites for spinal anaesthesia. 
 
               
        Figure 1.4: The layers that are passed through during insertion of spinal needle 
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When preparing for spinal anaesthetic blockade, it is important to find 
landmarks on the patient. The iliac crests usually mark the interspace between the fourth 
and fifth lumbar vertebrae, and a line can be drawn between them to help locate this 
interspace. Care must be taken to feel for the soft area between the spinous processes to 
locate the interspace. Depending on the level of anaesthesia necessary for the surgery 
and the ability to feel for the interspace, the L3-4 interspace or the L4-5 interspace can 
be used to introduce the spinal needle. Because the spinal cord ends at the L1 to L2 
level, it would not be wise to attempt spinal anaesthesia at or above this level. 
 
Figure 1.5: Correct positioning of patient during spinal anaesthesia 
 
Table 1.1: Clinical Pearls of spinal anaesthesia: 
The tenth thoracic (T10) dermatome corresponds to the umbilicus. 
The sixth thoracic (T6) dermatome corresponds to the xiphoid. 
The fourth thoracic (T4) dermatome corresponds to the nipples. 
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It would be incomplete to discuss surface anatomy without mentioning the 
dermatomes that are important for spinal anaesthesia. A dermatome is an area of skin 
innervated by sensory fibres from a single spinal nerve. The tenth thoracic (T10) 
dermatome corresponds to the umbilicus, the sixth thoracic (T6) dermatome the 
xiphoid, and the fourth thoracic (T4) dermatome the nipples. Figure 1.5 illustrates the 
dermatomes of the human body. To achieve surgical anaesthesia for a given procedure, 
the extent of spinal anaesthesia must reach a certain dermatomal level. Dermatomal 
levels of spinal anaesthesia for common surgical procedures are listed in Table 1.2. 
            
                              Figure 1.6: The dermatomes of the human body 
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Table 1.2: Dermatomal Levels of Spinal Anaesthesia for Common Surgical Procedures 
PROCEDURE DERMATOMAL LEVEL 
Upper abdominal surgery T4 
Intestinal, gynaecologic and urologic surgery T6 
Transurethral resection of the prostate  
Vaginal delivery of a fetus, and hip surgery T10 
Thigh surgery and lower leg amputations L1 
Foot and ankle surgery L2 
Perineal and anal surgery S2-S5 (saddle block) 
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1.3 Local Anaesthetics 
The choice of local anaesthetic is based on potency, onset, duration of 
anaesthesia, and side effects of the drug. Two distinct groups of local anaesthetics are 
used in spinal anaesthesia, esters and amides, which are characterized by the bond that 
connects the aromatic portion and the intermediate chain.  
 
Esters contain an ester link between the aromatic portion and the intermediate 
chain, and this includes drugs like procaine, chloroprocaine, and tetracaine. Amide 
groups contain an amide link between the aromatic portion and the intermediate chain, 
and this includes bupivacaine, ropivacaine, etidocaine, lidocaine, mepivacaine, and 
prilocaine. The drug metabolism is important in determining the activity of local 
anaesthetics, lipid solubility, protein binding, and pKa. 
 
Lipid solubility relates to the potency of local anaesthetics. Low lipid solubility 
indicates that higher concentrations of local anaesthesia must be given to obtain 
adequate blockade. High lipid solubility produces anaesthesia at low concentrations. 
Higher protein binding drugs results in longer duration of action. 
 
 The pKa of a local anaesthetic is the pH at which ionized and nonionized forms 
are present in equilibrium in a solution.The nonionized form allows the local anaesthetic 
to diffuse across the lipophilic nerve sheath and reach the sodium channels in the nerve 
membrane. The onset of anaesthesia relates to the amount of local anaesthetic available 
in the base form. The lower the pKa level of an anaesthetic drugs the faster the onset of 
action. 
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Pharmacokinetics of local anaesthetics includes uptake and elimination of the 
local anaesthetic. Four factors play a role in the uptake of local anaesthetics from the 
subarachnoid space into neuronal tissue; 
 (1) concentration of local anaesthetic in CSF, 
 (2) the surface area of nerve tissue exposed to CSF, 
 (3) lipid content of nerve tissue, and 
 (4) blood flow to nerve tissue. 
 
The uptake of local anaesthetic is greatest at the site of highest concentration in 
the CSF and is decreased above and below this site. Both the nerve roots and the spinal 
cord take up local anaesthetics after injection into the subarachnoid space. The wider 
surface area of the nerve root exposed, the greater the uptake of local anaesthetic. 
 
The spinal cord has two mechanisms for uptake of local anaesthetics. The first 
mechanism is by diffusion in the most superficial portion of the spinal cord, which is a 
slow process, from the CSF to the pia mater and into the spinal cord.  
 
The second method of local anaesthetic uptake is by extension into the spaces of 
Virchow-Robin, which are the areas of pia mater that surround the blood vessels 
penetrating the central nervous system.  
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 Figure 1.7: Representation of periarterial Virchow-Robin spaces around the spinal cord. 
 
Many factors affect the distribution of local anaesthetics in the subarachnoid 
space. The three most important factors for determining spread of local anaesthesia in 
the subarachnoid space are baricity of the local anaesthetic solution, position of the 
patient during and just after injection, and dose of the anaesthetic injected. 
 
Hypobaric solutions are less dense than CSF and tend to flow against gravity. 
Isobaric solutions are as dense as CSF and tend to remain at the level at which they are 
injected. Hyperbaric solutions are denser than CSF and tend to follow gravity after 
injection. 
 
Dose and volume both play a role in the spread of local anaesthetics after spinal 
injection. Concentration of local anaesthetic before injection has no bearing on 
distribution because after injection, due to the mixing of the CSF and local anaesthetic, 
there will be a new concentration. 
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Multiple factors affect the distribution of local anaesthesia after spinal blockade, 
one being CSF volume. Carpenter showed that lumbosacral CSF volume correlated with 
peak sensory block height and duration of surgical anaesthesia. Higuchi found that CSF 
density and lumbosacral CSF volume correlates to peak sensory block level, and onset 
and duration of motor block. However, due to the wide variability in CSF volume the 
ability to predict the level of the spinal blockade after local anaesthetic injection is very 
poor, even if body mass index (BMI) is calculated and used. 
 
Spinal anaesthesia is the most commonly used technique for lower limb 
surgeries as it is very economical and easy to administer. However, postoperative pain 
control is a major problem due to spinal anaesthesia being only a temporary spinal 
blockade and thus early analgesic intervention is needed in the postoperative period. 
Few number of adjuvant drugs such as clonidine, midazolam and others have been 
proven in studies to prolong the effect of spinal anaesthesia. 
 
A common problem during lower limb surgeries under spinal anaesthesia is 
nausea and vomiting. The addition of fentanyl to hyperbaric bupivacaine improves the 
quality of intraoperative and early postoperative subarachnoid block. The addition of 
opioids to local anaesthetic solution has disadvantages such as pruritus and respiratory 
depression. 
 
Dexmedetomidine, a new highly selective α2-agonist, is still under study as an 
alternative neuraxial adjuvant as it provides stable haemodynamic conditions, good  
intraoperative block coverage and prolonged postoperative analgesia with minimal side 
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effects. Dexmedetomidine has been approved by Food and Drug Administration (FDA) 
as a short term sedative for mechanically ventilated intensive care unit (ICU) patients. 
 
Based on earlier human studies, it is hypothesized that intrathecal 5 µg 
Dexmedetomidine would produce more postoperative analgesic effect with hyperbaric 
bupivacaine in spinal anaesthesia with minimal side effects. Till date, there has been no 
study comparing the addition of Dexmedetomidine to hyperbaric bupivacaine with 
fentanyl to hyperbaric bupivacaine, although various studies have compared 
Dexmedetomidine and fentanyl with isobaric bupivacaine. 
 
This study aims to investigate the effect of intrathecal administration of 
dexmedetomidine on the duration of sensory and motor block and postoperative 
analgesic requirements produced by spinal bupivacaine in lower limb orthopaedic 
surgery. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Pain 
2.1.1 Definition 
The "standard" definition of pain is that of the International Association for the 
Study of Pain (IASP):-  
 
"An unpleasant sensory or emotional experience associated with actual or potential 
tissue damage. Pain is subjective, different perception in different individual. Each 
individual learns the application of the word through experiences related to injury in 
any stage of life. It is a sensation in a part of the body, but it is unpleasant, and 
therefore is also known as an emotional experience. Many people present with pain in 
the absence of any tissue damage; usually this happens for psychological reasons. 
There is no way to picturise their experience from that due to tissue damage, if we take 
this as a subjective statement". (Wolff 1980) 
 
This definition is extremely broad and by concentrating on the subjective nature 
of pain, this definition allows us to conveniently ignore individuals whose physical 
findings are not at all consistent with a diagnosis of "pain", but who cannot relate a 
subjective feeling of pain. Indeed, it tells us that (appearances to the contrary) such 
people are not in pain!  
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2.1.2 Pain fibres 
Cutaneous sensation is mediated by specific sensory receptors that are located in 
the skin layer. These are broadly classified into low and high threshold primary 
afferents. The low threshold afferents are myelinated fibres with specialised nerve 
endings that convey innocuous sensations such as light touch, vibration, pressure (all 
Ab) and proprioception (Aa). High threshold afferents are thin myelinated (Ad) or 
unmyelinated (C) fibres located in the dermis and epidermis, which conveys 
pain and temperature sensation. 
 
Table 2.1: Comparative properties of primary afferent fibres 
Fibre 
class 
Threshold Main 
transmitters 
Main 
receptor 
activated 
Laminar 
location 
Target 
spinal 
cord 
neurones 
Normal 
sensation 
Pathological 
sensation 
C High Peptides NK1,2 I-II, V NS Slow 
pain 
Hyperalgesia 
Ad EAA NMDA 
AMPA 
mGlu 
WDR Fast pain Allodynia 
Ab Low EAA AMPA III-VI LT 
WDR 
Touch 
vibration 
pressure 
Mechanical 
allodynia 
Key: EAA = Excitatory amino acids; NS = Nociceptive specific; LT = Low threshold; 
WDR = wide dynamic range; NK = neurokinin (peptide) receptor; NMDA, AMPA, 
mGlu are different types of glutamate receptors 
 
Pain and temperature afferents are polymodal free nerve endings and do not 
have any specialised receptors. They respond to more than one stimulus, e.g. chemical, 
thermal or mechanical stimuli. Free nerve endings are present in all parts of the body 
except the interior of the bones and the interior of the brain itself.  
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In the cornea of the eye, only free nerve endings are found and abrasions of the 
cornea can be extremely painful. Most responds only to tissue damaging stimuli and are 
called nociceptors. Pain sensations can be broadly classified into sharp, stabbing, dull, 
throbbing and aching types. 
 
 Ad fibres mediate the former or ‘fast’ pain, C-fibres signal the latter or ‘slow 
pain’. Not all Ad and C fibres are nociceptors as some of them responds to low 
threshold stimuli such as touching or brushing of the skin. C fibres are thermoreceptors, 
and responds to warm or cold. 
 
Although pain results from damage to free nerve endings, but in reality the pain 
is a result of substances released by the damaged tissues: prostaglandins, histamine and 
peptides which activates the receptors located on the free nerve ends.(Cervero 1994) 
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2.1.3 Spinal cord 
The spinal cord consists of a grey and white matter. White matter contains 
ascending and descending fibres while the grey matter contains cells and central 
terminals of primary afferents from the periphery.  
  
The dorsal horn is divided into 6 layers (laminae) and processes sensory 
information. Lamina I is the most dorsal and consist of a thin layer of large cells and 
small inhibitory interneurons. The axons from this large cells forms a part of the 
spinothalamic tract. 
 
The second layer is lamina II or known as the “substantia gelatinosa”. Most of 
the cells here are inhibitory but excitatory cells are present as well.  This layer is 
believed to control the “connectivity” of the other laminae in the dorsal horn. Together, 
laminae I-II are known as the superficial dorsal horn and receives input from the 
nociceptors high threshold C and Ad fibres and contain cells that are nociceptive 
specific, NS (respond only to noxious stimuli) or wide dynamic range, WDR (respond 
to both innocuous and noxious stimuli). 
 
Laminae III-VI receives input from the cutaneous Ab non-nociceptive afferents 
and contains cells with low-threshold (LT) receptive fields that responds to innocuous 
stimuli. Some lamina V cells are WDRs that receive input from both low-threshold (Ab) 
sensory fibres and high-threshold (C, Ad) fibres as their dendrites project dorsally into 
laminae I-II.   
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The dorsal horn is not only transmits innocuous and noxious messages, it also 
has an important role in modulating pain transmission through spinal and supraspinal 
mechanisms. This regulatory circuit involves the primary afferents, spinal interneurons 
and descending fibres. (LIght and Perl 1980) 
 
                     
    Figure 2.1: Spinal cord transverse section showing lamina levels I -V 
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2.1.4 Pain pathways 
The first pain modulatory mechanism called the "Gate Control" theory was 
coined by Melzack and Wall in the mid 1960 whereby the concept states that non-
painful input closes the gates to painful input, which prevents the transmission of pain 
from travelling to  CNS (i.e., non-noxious input [stimulation] suppresses pain). 
(Melzack and Wall 1967). 
 
The theory suggests that collaterals of the large sensory fibres carrying 
cutaneous sensory input activate inhibitory interneurons, which inhibit (modulate) pain 
transmission information carried by the pain fibres.  
 
Non-noxious input suppresses pain, or sensory input “closes the gate” to noxious 
input. The gate theory predicts that at the spinal cord level, non-noxious input will lead 
to presynaptic inhibition on dorsal root nociceptor fibres that synapse on nociceptors 
spinal neurons (T), and this presynaptic inhibition will block incoming noxious 
information from reaching the CNS (i.e., will close the gate to incoming noxious 
information). 
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Figure 2.2: Gate control theory of pain. This figure shows the inhibitory interneurons 
(yellow) located in the substantia gelatinosa (SG) would determine whether nociceptive 
input from the periphery would be relayed through the spinal transmission system (red, 
T) to higher CNS areas whereby pain would be consciously perceived(Willis Jr 1985). 
 
Three classes of opioid receptors have been identified: μ-mu, δ-delta and κ-
kappa(Paterson, Robson et al. 1983) which are widely distributed in the brain. Genes 
encoding each one of them have been cloned and noted to be members of the G protein 
receptors. Three major classes of endogenous opioid peptides that interact with the 
above opiate receptors have also been recognized in the CNS: β-endorphins, 
enkephalins and the dynorphins. These opioid peptides are derived from a large protein 
precursor by three different genes: the proopiomelanocortin (POMC) gene, the 
proenkephalin gene and the prodynorphin gene.  
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These opioid peptides modulate the nociceptive input in two ways: 
1) it blocks neurotransmitter release by inhibiting Ca2+ influx into the presynaptic 
terminal, or 
2) open up the potassium channels, which hyperpolarizes neurons and inhibits spike 
activity.  
 
 They act on various receptors in the brain and spinal cord. These opioid 
peptides, enkephalins are considered as the putative ligands for the δ receptors, β 
endorphins for the μ-receptors, and dynorphins for the κ receptors. The opioid receptors 
are distributed differently within the central and peripheral nervous system and there are 
functional differences in these receptors in various structures. This explains the side 
effects following opiate treatments. For example, mu (μ) receptors are found 
widespread in the brain stem, parabrachial nuclei, which is a respiratory center and 
inhibition of these neurons elicits respiratory depression. 
 
Central or peripheral terminals of nociceptive afferent fibres contain opiate 
receptors where exogenous and endogenous opioids could act to modulate the ability to 
transmit nociceptive senasation. High densities of opiate receptors are found in 
periaqueductal gray (PAG), nucleus raphe magnus (NRM), and dorsal raphe (DR) in the 
rostral ventral medulla, in the spinal cord, caudate nucleus (CN), septal nucleus, 
hypothalamus, habenula and hippocampus. (Mansour, Khachaturian et al. 1988) 
 
 
